Stay updated on Pembrolizumab First-line in Advanced Merkel Cell Carcinoma Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab First-line in Advanced Merkel Cell Carcinoma Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab First-line in Advanced Merkel Cell Carcinoma Clinical Trial page

  1. Check
    yesterday
    No Change Detected
  2. Check
    2 days ago
    No Change Detected
  3. Check
    3 days ago
    No Change Detected
  4. Check
    4 days ago
    No Change Detected
  5. Check
    6 days ago
    Change Detected
    Summary
    The value of Revision has been updated from v2.8.0 to v2.8.1, indicating a recent revision in the content of the webpage.
    Difference
    0.1%
    Check dated 2024-06-13T21:18:40.000Z thumbnail image
  6. Check
    13 days ago
    Change Detected
    Summary
    The value 7 has recently changed to 8 on the webpage. This change likely represents an update in the number of participants enrolled in a clinical trial for pembrolizumab as first-line therapy for advanced Merkel Cell Carcinoma.
    Difference
    0.1%
    Check dated 2024-06-06T14:36:19.000Z thumbnail image
  7. Check
    28 days ago
    Change Detected
    Summary
    The 'Participation Criteria' section has been updated to include detailed eligibility criteria for participants, specifying age, health conditions, and prior treatments required for inclusion in the study. Previously, this section had no information provided.
    Difference
    39%
    Check dated 2024-05-22T21:33:30.000Z thumbnail image
  8. Check
    50 days ago
    Change Detected
    Difference
    0.9%
    Check dated 2024-04-30T22:51:50.000Z thumbnail image

Stay in the know with updates to Pembrolizumab First-line in Advanced Merkel Cell Carcinoma Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab First-line in Advanced Merkel Cell Carcinoma Clinical Trial page.